Early benefit assessment: Detailed analysis of all G-BA resolutions

The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.

List of all G-BA Resolutions

The AMNOG monitor includes detailed analyses of every sinlge benefit assessment since 2011. more >>

Interactive Analysis

Our comprehensive online analysis tool helps answer your individual questions. more >>

Intelligent search

Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>

Reimbursement Price Trends

See the development of manufacturer's prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>

Unrivalled AMNOG Process Knowledge

Gain relevant insights from our summary analysis and our evaluation of all AMNOG resolutions. more >>



Behalten Sie den Überblick

Identify decision-paths and trends in early benefit assessment. The AMNOG monitor is indispensable for managers and decision-makers in market access, pricing and reimbursement. 

Contact us for more information! >>


Dear AMNOG Monitor readers,

With a total of 21 decisions on the early benefit assessment, including 8 additional benefit resolutions, the G-BA again had an extensive program to complete in June: Several controversial decisions regarding quality assurance measures (ATMP-QS-RL) were noticeable: quality assurance measures were rejected for Voretigen Neparvovec, but approved for valoctocogene roxaparvovec and etranacogene dezaparvovec as gene therapies for haemophilia A and B, respectively, as well as for tabelecleucel for the treatment of Epstein-Barr virus-positive post-transplantation lymphoma (EBV+ PTLD) (all three without benefit assessment procedures according to §35a). The plenary also rejected the application for the collection of routine practice data (AbD) for the active substance Tafasitamab for the treatment of r/r diffuse large B-cell lymphoma (DLBCL).

In addition, existing time limits were lifted for Dabrafenib (4) and Trametinib (3) for the adjuvant treatment of adults after complete resection of BRAF V600-mutated stage III melanoma and for Pembrolizumab (8) for the adjuvant treatment of adults with stage III melanoma with lymph node involvement after complete resection. The time limits for Olaparib (5) in ovarian cancer and belantamab mafodotin for the advanced treatment of multiple myeloma were extended until the new trial data are available.

Two procedures were suspended until the ECJ conclusively clarifies questions regarding the protection of documents: Diroximelfumarat and Dimethylfumarat (13-17 years), both for multiple sclerosis.

In addition, 8 G-BA decisions on the early benefit assessment were made, which are shown in the following table. With Ripretinib, an orphan drug in oncology for the treatment of adults with advanced gastrointestinal stromal tumours (GIST) received an indication for major additional benefit. In the procedure on Zanubrutinib for the treatment of patients with Waldenström's disease, the G-BA decided that the submitted dossier was incomplete, so that no additional benefit could be given.

Recent changes in reimbursement prices of AMNOG products in November 2021 can be seen here.
A list of current EMA Positive Opinions for new drugs is available here.

Kind regards,
Dr Johannes Hankowitz and Christian Rieke